Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380404 | 0.84 | ALOX5 (0.33) | TDP1TSHRCYP2D6CTSDEPHX1 | |
| SCHEMBL13999457 | 0.81 | TDP1 (0.44) | TDP1PARP1SIGMAR1EPHX1KMT2A | |
| SCHEMBL13999460 | 0.81 | TDP1 (0.70) | TDP1PARP1SIGMAR1TSHRCYP2D6 | |
| SCHEMBL21706786 | 0.80 | BRD4 (0.39) | TDP1SIGMAR1TSHRSAT1KMT2A | |
| SCHEMBL104225 | 0.79 | — | — | |
| SCHEMBL17369631 | 0.79 | SIGMAR1 (0.45) | TDP1SIGMAR1SAT1KMT2A | |
| SCHEMBL13884246 | 0.79 | SIGMAR1 (0.45) | TDP1SIGMAR1SAT1KMT2A | |
| SCHEMBL17592586 | 0.79 | SAT1 (0.48) | TDP1DGAT1CYP2D6SAT1HSD11B1 | |
| SCHEMBL17592585 | 0.79 | SAT1 (0.48) | TDP1DGAT1CYP2D6SAT1HSD11B1 | |
| Hydrochloric Acid SCHEMBL21879609 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | TDP1 1394/4885PARP1 1965/4885SIGMAR1 2485/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | TDP1 1394/4885PARP1 1965/4885SIGMAR1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.